Table 4.
Univariate and multivariate analyses of variables associated with overall survival
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age (year), ≥70 versus <70 | 1.29 (0.70–2.40) | 0.413 | / | / |
| Hemoglobin (g l−1), <120 versus ≥120 | 1.70 (0.90–3.24) | 0.104 | / | / |
| ALP (U l−1), ≥160 versus <160 | 1.75 (0.91–3.35) | 0.095 | / | / |
| LDH (U l−1), ≥250 versus <250 | 1.33 (1.03–1.72) | 0.026 | 1.52 (0.79–2.08) | 0.321 |
| ALB (g−1), <35 versus ≥35 | 2.64 (1.29–5.42) | 0.008 | 2.43 (1.87–5.32) | 0.016 |
| ECOG performance status, ≥2 versus <2 | 1.84 (0.85–3.95) | 0.091 | / | / |
| Gleason score of primary lesion, ≥8 versus <8 | 1.09 (0.58–2.02) | 0.797 | / | / |
| Duration of previous hormonal therapy (month), <16.0 versus ≥16.0 | 1.05 (0.6–1.86) | 0.864 | / | / |
| Extent of metastatic sites, >5 versus 0–5 | 1.11 (0.64–1.94) | 0.714 | / | / |
| Visceral metastases, yes versus no | 2.38 (1.10–5.15) | 0.028 | 3.10 (1.32–4.88) | 0.042 |
| Previous docetaxel chemotherapy, yes versus no | 2.01 (1.14–3.54) | 0.016 | 1.46 (0.79–3.91) | 0.097 |
ALP: alkaline phosphatase; LDH: lactate dehydrogenase; ALB: albumin; ECOG: Eastern Cooperative Oncology Group; CI: confidence interval; HR: hazard ratios